Mark Oppenlander, M.D. Grant Support

Clinical study protocol to assess the safety and effectiveness of the Premia Spine TOPS system

Oppenlander M
Premia Spine
7/19/2019 – 4/30/2024


A study to investigate the safety, tolerability, pharmacokinetics of single ascending dose of MT-3921 in subjects with acute spinal cord injury

Oppenlander M
DP Clinical, Inc.
4/8/2020 - 4/30/2022

Principal Investigator

Mark E. Oppenlander, M.D.

Mark E. Oppenlander, M.D.

Clinical Associate Professor, Neurological Surgery
Clinical Associate Professor, Orthopaedic Surgery
734-936-7010